Nature Reviews Clinical Oncology最新文献

筛选
英文 中文
cfDNA screening for fetal aneuploidy facilitates maternal cancer detection 胎儿非整倍体cfDNA筛查有助于发现母体癌症
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-01-02 DOI: 10.1038/s41571-024-00981-0
David Killock
{"title":"cfDNA screening for fetal aneuploidy facilitates maternal cancer detection","authors":"David Killock","doi":"10.1038/s41571-024-00981-0","DOIUrl":"10.1038/s41571-024-00981-0","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 2","pages":"79-79"},"PeriodicalIF":81.1,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL 在化疗基础上加用blinatumomab可降低标准风险儿科B-ALL的复发风险
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-12-17 DOI: 10.1038/s41571-024-00980-1
Peter Sidaway
{"title":"Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00980-1","DOIUrl":"10.1038/s41571-024-00980-1","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 2","pages":"79-79"},"PeriodicalIF":81.1,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease Ipilimumab联合nivolumab对dMMR/MSI-H疾病患者有效
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-12-11 DOI: 10.1038/s41571-024-00978-9
Peter Sidaway
{"title":"Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00978-9","DOIUrl":"10.1038/s41571-024-00978-9","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 2","pages":"79-79"},"PeriodicalIF":81.1,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer T细胞动力学与新辅助免疫治疗头颈癌
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-12-10 DOI: 10.1038/s41571-024-00969-w
Maryann Zhao, Jonathan D. Schoenfeld, Ann Marie Egloff, Glenn J. Hanna, Robert I. Haddad, Douglas R. Adkins, Ravindra Uppaluri
{"title":"T cell dynamics with neoadjuvant immunotherapy in head and neck cancer","authors":"Maryann Zhao, Jonathan D. Schoenfeld, Ann Marie Egloff, Glenn J. Hanna, Robert I. Haddad, Douglas R. Adkins, Ravindra Uppaluri","doi":"10.1038/s41571-024-00969-w","DOIUrl":"10.1038/s41571-024-00969-w","url":null,"abstract":"Immune-checkpoint inhibitors (ICIs) are being tested as neoadjuvant therapies in various solid tumours, including in patients with head and neck squamous cell carcinoma (HNSCC), with promising results. Key findings thus far include that this approach is well-tolerated with favourable clinical outcomes including promising pathological response rates in initial studies. Pathological responses are likely to be increased by combining other agents with anti-PD-(L)1 antibodies. Comparisons of baseline biopsy samples with post-treatment surgical specimens have enabled correlative studies utilizing multiomic and immunogenomic methods. Data from these studies suggest that pretreatment intratumoural tissue-resident memory CD8+ T cells are key drivers of tumour regression and give rise to both local and systemic antitumour immune responses. Analyses of systemic responses have defined a PD-1+KLRG1− circulating CD8+ T cell subpopulation that is highly predictive of response, and revealed the interrelationships between intratumoural clones and circulating CD8+ T cells. Lastly, interrogation of T cell populations within lymph nodes is beginning to delineate the immune crosstalk between the primary tumour and tumour-draining lymph nodes and how this relationship might be disrupted with tumour infiltration of the latter. In this Review, we examine data from trials testing neoadjuvant ICIs in patients with HNSCC, focusing on human papillomavirus-unrelated disease, and highlight correlative immunogenomic findings from these trials. Neoadjuvant administration of immune-checkpoint inhibitors (ICIs) has substantially improved the outcomes in patients with various solid tumours, including those with head and neck cancer. However, not all patients derive benefit, indicating a need for biomarkers that enable accurate predictions of a response to these agents. In this Review the authors describe changes in both intratumour and circulating T cells in patients with locally advanced head and neck cancer receiving neoadjuvant ICIs, and consider the role of specific T cell subsets as biomarkers in this setting.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 2","pages":"83-94"},"PeriodicalIF":81.1,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leptomeningeal metastatic disease: new frontiers and future directions 轻脑膜转移性疾病:新领域和未来方向
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-12-09 DOI: 10.1038/s41571-024-00970-3
Ahmad Ozair, Hannah Wilding, Debarati Bhanja, Nicholas Mikolajewicz, Michael Glantz, Stuart A. Grossman, Arjun Sahgal, Emilie Le Rhun, Michael Weller, Tobias Weiss, Tracy T. Batchelor, Patrick Y. Wen, Daphne A. Haas-Kogan, Mustafa Khasraw, Roberta Rudà, Riccardo Soffietti, Philipp Vollmuth, Vivek Subbiah, Chetan Bettegowda, Lily C. Pham, Graeme F. Woodworth, Manmeet S. Ahluwalia, Alireza Mansouri
{"title":"Leptomeningeal metastatic disease: new frontiers and future directions","authors":"Ahmad Ozair, Hannah Wilding, Debarati Bhanja, Nicholas Mikolajewicz, Michael Glantz, Stuart A. Grossman, Arjun Sahgal, Emilie Le Rhun, Michael Weller, Tobias Weiss, Tracy T. Batchelor, Patrick Y. Wen, Daphne A. Haas-Kogan, Mustafa Khasraw, Roberta Rudà, Riccardo Soffietti, Philipp Vollmuth, Vivek Subbiah, Chetan Bettegowda, Lily C. Pham, Graeme F. Woodworth, Manmeet S. Ahluwalia, Alireza Mansouri","doi":"10.1038/s41571-024-00970-3","DOIUrl":"10.1038/s41571-024-00970-3","url":null,"abstract":"Leptomeningeal metastatic disease (LMD), encompassing entities of ‘meningeal carcinomatosis’, neoplastic meningitis’ and ‘leukaemic/lymphomatous meningitis’, arises secondary to the metastatic dissemination of cancer cells from extracranial and certain intracranial malignancies into the leptomeninges and cerebrospinal fluid. The clinical burden of LMD has been increasing secondary to more sensitive diagnostics, aggressive local therapies for discrete brain metastases, and improved management of extracranial disease with targeted and immunotherapeutic agents, resulting in improved survival. However, owing to drug delivery challenges and the unique microenvironment of LMD, novel therapies against systemic disease have not yet translated into improved outcomes for these patients. Underdiagnosis and misdiagnosis are common, response assessment remains challenging, and the prognosis associated with this disease of whole neuroaxis remains extremely poor. The dearth of effective therapies is further challenged by the difficulties in studying this dynamic disease state. In this Review, a multidisciplinary group of experts describe the emerging evidence and areas of active investigation in LMD and provide directed recommendations for future research. Drawing upon paradigm-changing advances in mechanistic science, computational approaches, and trial design, the authors discuss domain-specific and cross-disciplinary strategies for optimizing the clinical and translational research landscape for LMD. Advances in diagnostics, multi-agent intrathecal therapies, cell-based therapies, immunotherapies, proton craniospinal irradiation and ongoing clinical trials offer hope for improving outcomes for patients with LMD. Leptomeningeal metastatic disease (LMD) arises secondary to the metastatic dissemination of cancer cells into the leptomeninges and cerebrospinal fluid. Novel therapies against systemic disease have not yet translated into improved outcomes for patients with LMD, in whom median survival after diagnosis remains at 2–6 months. The authors of this Review, a multidisciplinary group of experts, describe the emerging evidence and areas of active investigation in LMD and provide directed recommendations for future research.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 2","pages":"134-154"},"PeriodicalIF":81.1,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthetic lethal strategies for the development of cancer therapeutics 癌症治疗发展的合成致死策略
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-12-03 DOI: 10.1038/s41571-024-00966-z
Natalie Y. L. Ngoi, David Gallo, Carlos Torrado, Mirella Nardo, Daniel Durocher, Timothy A. Yap
{"title":"Synthetic lethal strategies for the development of cancer therapeutics","authors":"Natalie Y. L. Ngoi, David Gallo, Carlos Torrado, Mirella Nardo, Daniel Durocher, Timothy A. Yap","doi":"10.1038/s41571-024-00966-z","DOIUrl":"10.1038/s41571-024-00966-z","url":null,"abstract":"Synthetic lethality is a genetic phenomenon whereby the simultaneous presence of two different genetic alterations impairs cellular viability. Importantly, targeting synthetic lethal interactions offers potential therapeutic strategies for cancers with alterations in pathways that might otherwise be considered undruggable. High-throughput screening methods based on modern CRISPR–Cas9 technologies have emerged and become crucial for identifying novel synthetic lethal interactions with the potential for translation into biologically rational cancer therapeutic strategies as well as associated predictive biomarkers of response capable of guiding patient selection. Spurred by the clinical success of PARP inhibitors in patients with BRCA-mutant cancers, novel agents targeting multiple synthetic lethal interactions within DNA damage response pathways are in clinical development, and rational strategies targeting synthetic lethal interactions spanning alterations in epigenetic, metabolic and proliferative pathways have also emerged and are in late preclinical and/or early clinical testing. In this Review, we provide a comprehensive overview of established and emerging technologies for synthetic lethal drug discovery and development and discuss promising therapeutic strategies targeting such interactions. The experience with PARP inhibitors provides evidence of the clinical utility of synthetic lethality, whereby the simultaneous presence of two specific alterations is required for antitumour activity. In this Review, the authors describe attempts to identify novel synthetic lethal interactions, including the role of emerging technologies in identifying new synthetic lethal relationships as well as novel agents that are currently being tested in clinical trials that might extend the clinical relevance of synthetic lethality beyond PARP inhibitors.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 1","pages":"46-64"},"PeriodicalIF":81.1,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00966-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142760331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer 围手术期nivolumab对局部晚期可切除的非小细胞肺癌患者具有良好的长期预后
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-12-03 DOI: 10.1038/s41571-024-00976-x
Tina Cascone, William N. William Jr.
{"title":"Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer","authors":"Tina Cascone, William N. William Jr.","doi":"10.1038/s41571-024-00976-x","DOIUrl":"10.1038/s41571-024-00976-x","url":null,"abstract":"As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes and that a pCR following neoadjuvant therapy translates into improved long-term survival. These data support the development of novel, personalized treatments for locally advanced resectable NSCLC.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 2","pages":"81-82"},"PeriodicalIF":81.1,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142760484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Getting the right combination to break the epigenetic code 找到正确的组合来破解表观遗传密码
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-12-02 DOI: 10.1038/s41571-024-00972-1
Seda S. Tolu, Aaron D. Viny, Jennifer E. Amengual, Barbara Pro, Susan E. Bates
{"title":"Getting the right combination to break the epigenetic code","authors":"Seda S. Tolu, Aaron D. Viny, Jennifer E. Amengual, Barbara Pro, Susan E. Bates","doi":"10.1038/s41571-024-00972-1","DOIUrl":"10.1038/s41571-024-00972-1","url":null,"abstract":"Rapid advances in the field of epigenetics have facilitated the development of novel therapeutics targeting epigenetic mechanisms that are hijacked by cancer cells to support tumour growth and progression. Several epigenetic agents have been approved by the FDA for the treatment of cancer; however, the efficacy of these drugs is dependent on the underlying biology and drivers of the disease, with inherent differences between solid tumours and haematological malignancies. The efficacy of epigenetic drugs as single agents remains limited across most cancer types, which has spurred the clinical development of combination therapies, with the hope of attaining synergistic activity and/or overcoming treatment resistance. In this Review we discuss clinical advances that have been achieved with the use of epigenetic agents in combination with chemotherapies, immunotherapies or other targeted agents, including epigenetic–epigenetic combinations, as well as limitations and challenges associated with these combinatorial strategies. So far, the success of combination therapies targeting epigenetic mechanisms has generally been confined to haematological malignancies, with limited efficacy observed in patients with solid tumours. Nevertheless, this Review captures the field of epigenetic combination therapies across the spectra of haematology and oncology, highlighting opportunities for precision therapy to effectively harness the potential of epigenetic agents and produce meaningful improvements in clinical outcomes. Increased recognition of the roles of epigenetic reprogramming in cancer has spurred the development of epigenetic therapies, although these drugs have meaningful efficacy as single agents in only a narrow range of malignancies. In this Review, the authors discuss advances and pitfalls in the use of epigenetic drugs combined with chemotherapies, immunotherapies or other targeted agents, including epigenetic–epigenetic combinations.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 2","pages":"117-133"},"PeriodicalIF":81.1,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142760314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer egfr突变型非小细胞肺癌治疗前景的变化
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-11-29 DOI: 10.1038/s41571-024-00971-2
Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel S. W. Tan, Suresh S. Ramalingam, Caicun Zhou
{"title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","authors":"Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel S. W. Tan, Suresh S. Ramalingam, Caicun Zhou","doi":"10.1038/s41571-024-00971-2","DOIUrl":"10.1038/s41571-024-00971-2","url":null,"abstract":"The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation EGFR TKIs, which are often characterized by potent central nervous system penetrance, are the standard-of-care first-line treatment for advanced-stage EGFR-mutant NSCLC. Rational combinations of third-generation EGFR TKIs with anti-angiogenic drugs, chemotherapy, the EGFR–MET bispecific antibody amivantamab or local tumour ablation are being investigated as strategies to delay drug resistance and increase clinical benefit. Furthermore, EGFR TKIs are being evaluated in patients with early stage or locally advanced EGFR-mutant NSCLC, with the ambitious aim of achieving cancer cure. Despite the inevitable challenge of acquired resistance, emerging treatments such as new TKIs, antibody–drug conjugates, new immunotherapeutic approaches and targeted protein degraders have shown considerable promise in patients with progression of EGFR-mutant NSCLC on or after treatment with EGFR TKIs. In this Review, we describe the current first-line treatment options for EGFR-mutant NSCLC, provide an overview of the mechanisms of acquired resistance to third-generation EGFR TKIs and explore novel promising treatment strategies. We also highlight potential avenues for future research that are aimed at improving the survival outcomes of patients with this disease. Third-generation EGFR tyrosine-kinase inhibitors (TKIs) are the standard-of-care first-line treatment for patients with advanced-stage EGFR-mutant NSCLC and their efficacy is being investigated in early stage and locally advanced disease. The authors of this Review describe the current first-line treatment options for EGFR-mutant NSCLC, discuss mechanisms of acquired resistance to third-generation EGFR TKIs and new promising treatment strategies, such as bispecific antibodies, next-generation TKIs, antibody–drug conjugates, immunotherapy approaches and targeted protein degraders.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 2","pages":"95-116"},"PeriodicalIF":81.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142753222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL 符合移植条件的R/R DLBCL患者使用格列菲坦单抗加化疗可获益
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-11-28 DOI: 10.1038/s41571-024-00975-y
Diana Romero
{"title":"Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL","authors":"Diana Romero","doi":"10.1038/s41571-024-00975-y","DOIUrl":"10.1038/s41571-024-00975-y","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 1","pages":"2-2"},"PeriodicalIF":81.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142735665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信